The state of California will take significant steps forward to increase insulin access and affordability – beginning January 1, 2026, CalRx will offer a box of five insulin pens for $55 to anyone who needs it. California announced that Civica will contract with India-based biosimilar manufacturer Biocon to fulfill its commitment to bring low-cost insulin glargine (a long-acting and not name-brand insulin) to California through the CalRx label. Read more
On Thursday, September 25, 2025, T1International brought policy leaders, advocates, and patients together at NYU Law for “Fixing a Broken System: The Path to Public Pharma in New York,” a major public event highlighting the urgent need for publicly controlled pharmaceutical production to counter skyrocketing drug prices. Read more
At T1International, over a decade of grassroots organizing, storytelling, advocacy, and action have brought us to this critical moment. Our community has grown to include people with diabetes, caregivers, and allies from over 150 countries, all united by a shared vision: a world where everyone has the access to the insulin, supplies, and care they need to survive and truly live. Read more
The recently passed “One Big Beautiful Bill” represents the largest and greatest healthcare loss in American history, cutting health care for 17 million people living in this country. This bill, passed in the United States Congress today, is a profound and deadly cut for people living with diabetes, their families, and marginalized and disabled people across the country.
Read more
On May 2, 2025, #insulin4all advocates, including T1International’s Executive Director Shaina Kasper, participated in a high-level United Nations hearing to shape the agenda for the upcoming Political Declaration on noncommunicable diseases. In remarks, Kasper called on UN member states to urgently address insulin affordability, support public manufacturing, and center patients in global diabetes policy decisions. Emphasizing that the insulin crisis is far from over, she highlighted patient stories from around the world and urged bold action to ensure equitable access to lifesaving diabetes care. Read more